Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin

Inflammation Research

Volumn 52, Issue 6, 2003, Pages 238-245

  Dvorak, M ^a,b   Watkinson, A ^a   McGlone, F ^a   Rukwied, R ^a,c  

^a UNILEVER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cannabinoid receptor agonist HU210; Histamine; Inflammation; Itch; Microdialysis

Indexed keywords

CANNABINOID RECEPTOR AGONIST; DEXANABINOL; HISTAMINE;

ADULT; ARTICLE; CONTROLLED STUDY; EXTRAVASATION; HUMAN; HUMAN EXPERIMENT; IONTOPHORESIS; MALE; MICRODIALYSIS; NERVE FIBER; NORMAL HUMAN; PROTEIN SECRETION; PRURITUS; SKIN BLOOD FLOW;

EID: 0037709373     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1162-z     Document Type: Article

References (54)

1. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003-8.
2. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjörk HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuro Report 2000; 11: 645-8.
3. Aaronson DW Comparative efficacy of H1 antihistamines. Ann Allergy 1991; 67: 541-7.
4. Advenier C, Queille Roussel C. Rational use of antihistamines in allergic dermatological conditions. Drugs 1989; 38: 634-44.
5. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl Stockh 1991; 165: 1-53.
6. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editor. Cannabinoids as Therapeutic Agents. CRC Press Inc, Boca Raton, Florida, 1986: 1-19.
7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
8. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice ASC, Elphick MR. Cannabinoid CB1 receptor expression in rat spinal cord. Molecular and Cellular Neuroscience 2000; 15: 510-21.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
10. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. PNAS 1999; 96: 12198-203.
11. Calignano A, La Rana G, Loubet-Lescoulie P, Piomelli D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog Brain Res 2000; 129: 471-82.
12. Fuentes JA, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J. Cannabinoids as potential new analgesics. Life Sciences 1999; 65: 675-85.
13. Herkenham M, Lynn AB, Little MD, Ross Johnson M, Melvin LS, De Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
14. Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 1999; 65: 597-605.
15. Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience 2002; 110: 747-53.
16. Klein TW, Newton CA, Friedman H. Cannabinoids and the immune system. Pain Res Manag 2001; 6: 95-101.
17. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
18. Jagger SI, Hasnie FS, Sellaturay S, Rice ASC, The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmithoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-99.
19. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-9.
20. Guhring H, Schuster J, Hamza M, Ates M, Kotalla CE, Brune K. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol 2001; 429: 127-34.
21. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
22. Rukwied R, Watkinson A, McGlone F, Dvorak M Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; in press.
23. Magerl W, Westerman KA, Mohner B, Handwerker HO. Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. J Invest. Dermatol. 1990; 94: 347-52.
24. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neuroscience Letters 1997; 230: 117-20.
25. Bradford MM. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry 1976; 72: 248-54.
26. Nischik M, Forster C. Analysis of skin erythema using true color images. IEEE Trans Med Imaging 1997; 16: 711-6.
27. Handwerker HO, Forster C, Kirchhoff C. Discharge patterns of human C-fibers induced by itching and burning stimuli. J Neurophysiol 1991; 66: 307-15.
28. Amann R, Schuligoi R, Lanz I, Donnerer J. Histamine Induced Edema in the Rat Paw Effect of Capsaicin Denervation and a CGRP Receptor Antagonist. Eur J Pharmacol 1995; 279: 227-31.
29. Clough GF, Bennett AR, Church MK. Measurement of nitric oxide concentration in human skin in vivo using dermal microdialysis. Exp Physiol 1998; 83: 431-4.
30. Fiscus RR. Molecular mechanisms of endothelium-mediated vasodilation. Semin Thromb Hemost 1988; 14 Suppl: 12-22.
31. Amano R, Hiruma H, Nishida S, Kawakami T, Shimizu K. Inhibitory effect of histamine on axonal transport in cultured mouse dorsal root ganglion neurons. Neurosci Res 2001; 41: 201-6.
32. 3 receptor agonist R α methylhistamine in human skin. Br J Dermatol 1998; 138: 622-6.
33. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS et al. Acute Effects of Substance P and Calcitonin Gene-Related Peptide in Human Skin - A Microdialysis Study. J Invest Dermatol 2000; 115: 1015-20.
34. Bull HA, Hothersall J, Chowdhury N, Cohen J, Dowd PM. Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. J Invest Dermatol 1996; 106: 655-60.
35. Heyer G, Magerl W. Skin reactions and sensations induced by intradermal injection of substance P into compound 48/80 pretreated skin. In: Altmeyer K., Hoffman S., El Gammal, Hutchinson S., (editors). Wound healing and skin physiology. Berlin/Heidelberg/NewYork: Springer-Verlag, 1995: 335-44.
36. Brain SD, Williams TJ. Substance P regulates the vasodilator activity of calcitonin gene-related peptide. Nature 1988; 335: 73-5.
37. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E-2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999; 89: 901-7.
38. Averbeck B, Reeh PW. Interactions of inflammatory mediators stimulating release of calcitonin gene-related peptide, substance P and prostaglandin E-2 from isolated rat skin. Neuropharmacology 2001; 40: 416-23.
39. Neisius U, Olsson R, Rukwied R, Lischetzki G, Schmelz M. Prostaglandin E-2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. J Am Acad Dermatol 2002; 47: 28-32.
40. Sauer SK, Averbeck B, Reeh PW. Denervation and NKI receptor block modulate stimulated CGRP and PGE(2) release from rat skin. NeuroReport 2000; 11: 283-6.
41. Brzozowski T, Drozdowicz D, Szlachcic A, Pytko-Polonczyk J, Majka J, Konturek SJ. Role of nitric oxide and prostaglandins in gastroprotection induced by capsaicin and papaverine. Digestion 1993; 54: 24-31.
42. Kress M, Guthmann C, Averbeck B, Reeh PW. Calcitonin gene-related peptide and prostaglandin E-2 but not substance P release induced by antidromic nerve stimulation from rat skin in vitro. Neuroscience 1999; 89: 303-10.
43. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid Receptors Are Coupled to Nitric Oxide Release in Invertebrate Immunocytes, Microglia, and Human Monocytes. J Biol Chem 1996; 271: 19238-42.
44. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
45. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129: 227-30.
46. Martin BR. Cellular Effects of Cannabinoids. Pharmacol Rev 1999; 38: 45-74.
47. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339: 53-61.
48. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48: 443-50.
49. Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 2002; 22: 3864-72.
50. Clough GF, Bennett AR, Church MK. Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. BR J Dermatol 1998; 138: 806-14.
51. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators others than histamine induce pruritus in atopic dermatitis patients: a microdialysis study. Br J Dermatol 2000; 142: 1114-20.
52. Schmelz M, Petersen LJ. Neurogenic inflammation in human and rodent skin. News Physiol Sci 2001; 16: 33-7.
53. Lischetzki G, Rukwied R, Handwerker HO, Schmelz M. Nociceptor activation and protein extravasation induced by inflammatory mediators in human skin. Eur J Pain 2001; 5: 49-57.
54. Michel CC. Microvascular permeability, venous stasis and oedema. Int Angiol 1989; 8: 9-13.